Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 917

1.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC).

Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28.

PMID:
29955943
2.

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26.

PMID:
29946911
3.

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group.

Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30.

PMID:
29713954
4.

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.

Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese E.

Ann Hematol. 2018 Aug;97(8):1357-1367. doi: 10.1007/s00277-018-3295-8. Epub 2018 Mar 20.

5.

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.

Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, Wardelmann E.

PLoS One. 2018 Feb 16;13(2):e0193048. doi: 10.1371/journal.pone.0193048. eCollection 2018.

6.

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y.

Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23.

PMID:
29362980
7.

Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.

Rashid N, Koh HA, Lin KJ, Stwalley B, Felber E.

J Oncol Pharm Pract. 2018 Jun;24(4):253-263. doi: 10.1177/1078155217697484. Epub 2017 Mar 10.

PMID:
29284347
8.

Bosutinib more effective than imatinib in CML.

Gourd E.

Lancet Oncol. 2017 Dec;18(12):e716. doi: 10.1016/S1470-2045(17)30840-9. Epub 2017 Nov 9. No abstract available.

PMID:
29129440
9.

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.

PMID:
29030092
10.

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW.

Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.

11.

Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.

Hedenström P, Nilsson B, Demir A, Andersson C, Enlund F, Nilsson O, Sadik R.

World J Gastroenterol. 2017 Aug 28;23(32):5925-5935. doi: 10.3748/wjg.v23.i32.5925.

12.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
13.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.

14.

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.

Br J Cancer. 2017 Oct 24;117(9):1278-1285. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29.

15.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE.

Blood. 2017 Nov 9;130(19):2084-2091. doi: 10.1182/blood-2017-07-792143. Epub 2017 Aug 23.

16.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

17.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.

PMID:
28725989
18.

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Am J Hematol. 2017 Oct;92(10):E623-E625. doi: 10.1002/ajh.24865. Epub 2017 Aug 17. No abstract available.

19.

Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.

Zhao Y, Wang J, Luo Y, Shi J, Zheng W, Tan Y, Cai Z, Huang H.

Ann Hematol. 2017 Aug;96(8):1353-1360. doi: 10.1007/s00277-017-3021-y. Epub 2017 Jun 17.

PMID:
28624905
20.

Imatinib mesylate in desmoplastic small round cell tumors.

De Sanctis R, Bertuzzi A, Bisogno G, Carli M, Ferrari A, Comandone A, Santoro A.

Future Oncol. 2017 Jun;13(14):1233-1237. doi: 10.2217/fon-2016-0305. Epub 2017 Jun 7.

PMID:
28589771

Supplemental Content

Loading ...
Support Center